Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer

Phase 3

Completed

Conditions: Small Cell Lung Carcinoma Extensive Disease

Interventions: Drug: Durvalumab
Drug: Cisplatin
Drug: Etoposide
Drug: Carboplatin

First Posted Date: 2021-01-15

Last Posted Date: 2023-07-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 101

Registration Number: NCT04712903

Locations: 🇪🇸
Research Site, Zaragoza, Spain

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide
Drug: Durvalumab
Drug: Ceralasertib

First Posted Date: 2021-01-07

Last Posted Date: 2024-10-26

Lead Sponsor: Muhammad Furqan

Target Recruit Count: 30

Registration Number: NCT04699838

Locations: 🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 2 locations

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

Phase 3

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Biological: Pembrolizumab
Biological: Enfortumab vedotin (EV)
Drug: Gemcitabine
Procedure: RC + PLND
Drug: Cisplatin

First Posted Date: 2021-01-07

Last Posted Date: 2024-12-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 808

Registration Number: NCT04700124

Locations: 🇯🇵
Gifu University Hospital ( Site 1513), Gifu, Japan
🇷🇺
Volgograd Regional Uronephrological Center ( Site 0870), Volzhsky, Volgogradskaya Oblast, Russian Federation
🇺🇦
Municipal Non-profit Enterprise of Kharkiv Regional Council RCSDRPP ( Site 0965), Kharkiv, Kharkivska Oblast, Ukraine

and more 185 locations

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Phase 1

Recruiting

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: T-DXd
Biological: Durvalumab
Drug: Rilvegostomig
Drug: Carboplatin
Drug: Cisplatin
Drug: Volrustomig
Drug: Pemetrexed

First Posted Date: 2020-12-28

Last Posted Date: 2024-12-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 244

Registration Number: NCT04686305

Locations: 🇹🇷
Research Site, Bornova-Izmir, Turkey

Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma

Not Applicable

Not yet recruiting

Conditions: Cervical Squamous Cell Carcinoma

Interventions: Drug: Nimotuzumab
Radiation: External-beam radiation
Drug: Cisplatin
Radiation: Brachytherapy

First Posted Date: 2020-12-22

Last Posted Date: 2020-12-22

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 286

Registration Number: NCT04678791

Locations: 🇨🇳
Peking University 3rd Hospital, Beijing, Beijng, China

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

Phase 2

Completed

Conditions: Biliary Tract Cancer

Interventions: Drug: Atezolizumab
Other: Placebo
Drug: Bevacizumab
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2020-12-21

Last Posted Date: 2024-07-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 162

Registration Number: NCT04677504

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Duke Cancer Center, Durham, North Carolina, United States
🇺🇸
City of Hope Cancer Center, Duarte, California, United States

and more 46 locations

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Phase 3

Terminated

Conditions: Gastric Adenocarcinoma

Interventions: Drug: Sintilimab
Drug: Cisplatin
Drug: 5-fluorouracil
Drug: Ramucirumab
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2020-12-19

Last Posted Date: 2023-03-02

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 36

Registration Number: NCT04675983

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recurrent Oral Cavity Squamous Cell Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Oropharyngeal Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Procedure: Computed Tomography
Biological: Pembrolizumab
Radiation: Intensity-Modulated Radiation Therapy
Procedure: Magnetic Resonance Imaging
Radiation: Proton Beam Radiation Therapy

First Posted Date: 2020-12-17

Last Posted Date: 2024-12-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 188

Registration Number: NCT04671667

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 143 locations

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

Phase 2

Active, not recruiting

Conditions: Untreated Resectable Pancreatic Adenocarcinoma
Borderline Resectable Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Adenocarcinoma

Interventions: Drug: Paclitaxel protein bound
Drug: Gemcitabine
Drug: Cisplatin
Drug: Hydroxychloroquine

First Posted Date: 2020-12-16

Last Posted Date: 2024-10-14

Lead Sponsor: HonorHealth Research Institute

Target Recruit Count: 19

Registration Number: NCT04669197

Locations: 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

Phase 3

Active, not recruiting

Conditions: Urinary Bladder Neoplasms

Interventions: Biological: Cetrelimab
Drug: Cisplatin
Drug: TAR-200
Drug: Gemcitabine
Radiation: Conventional radiation therapy
Radiation: Hypo-fractioned radiation therapy

First Posted Date: 2020-12-09

Last Posted Date: 2024-12-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 518

Registration Number: NCT04658862

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇦🇷
Centro Oncologico Riojano Integral (Cori), La Rioja, Argentina
🇧🇷
Fundacao Pio XII, Barretos, Brazil

and more 290 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy